Level D· Scientific groundwork from lab and animal studiesAnimal StudyPubMedOpen access

Dose-specific efficacy of adipose-derived mesenchymal stem cells in septic mice.

Li K., Wang T., Li R., Xue F., Zeng G., Zhang J.

Animal Study on Systemic / IV, published in Stem Cell Res Ther (2023) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Animal Study
Journal
Stem Cell Res Ther (2023)
Country
England
Reported sample size
—
Source database
PubMed
PMID
36804962
PMCID
PMC9940377
DOI
10.1186/s13287-023-03253-3
Citations
12

Abstract (original English)

Background Mesenchymal stem cells (MSCs) therapy for sepsis has been extensively studied in the past decade; however, the treatment regimen and mechanism of action of MSCs remain elusive. Here, we attempted to understand the efficacy and mechanism of action of MSCs on rescuing mice with sepsis. Methods A mouse model of sepsis was produced by cecal ligation and puncture (CLP). Allogeneic adipose-derived MSCs (ADSCs) were administered by intravenous infusion at 6 h after CLP, and dose-related effects of ADSCs on these mice were determined by survival rate, histopathological changes, biochemical and coagulation parameters, bacterial load, and plasma levels of endotoxin and inflammatory cytokines. The tissue distribution of intravenously infused ADSCs in septic mice was investigated by pre-labeling ADSCs with the lipophilic membrane dye PKH26. RNA sequencing analysis was performed to assess the transcriptional changes in peripheral blood mononuclear cells (PBMCs) and the liver. Results A significant therapeutic effect of ADSCs at a dose of 2 × 10 7 cells/kg in septic mice was evidenced by a remarkable reduction in mortality (35.89% vs. 8.89% survival rate), blood bacterial burden, systemic inflammation, and multiple organ damage. In contrast, ADSCs at a lower dose (1 × 10 7 cells/kg) failed to achieve any beneficial outcomes, while ADSCs at a higher dose (4 × 10 7 cells/kg) caused

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is preclinical work; animal or laboratory results cannot be applied to humans.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence
MiceAnimalsLeukocytes, MononuclearCytokinesSepsisMesenchymal Stem CellsMesenchymal Stem Cell TransplantationMice, Inbred C57BLOrganic Chemicals

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research